(Q43228695)

16 November 2017

0 references

Bevacizumab vs ranibizumab-an appraisal of the evidence from CATT and IVAN. (English)

1 reference

16 November 2017

1 reference

F G Ahfat

1

1 reference

16 November 2017

F H Zaidi

series ordinal

2

1 reference

16 November 2017

language of work or name

1 reference

1 March 2013

1 reference

16 November 2017

1 reference

16 November 2017

27

1 reference

16 November 2017

3

1 reference

16 November 2017

289-290

1 reference

https://scigraph.springernature.com/pub.10.1038/eye.2013.1

16 November 2017

0 references

cites work

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

The miracle of DICE therapy for acute stroke: fact or fictional product of subgroup analysis?

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3597894

RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2

15 August 2018

1 reference

12 December 2020

Cerebrovascular accidents in ranibizumab

1 reference

12 December 2020

Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

1 reference

12 December 2020

Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study

1 reference

12 December 2020

Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/EYE.2013.1

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference

16 November 2017

1 reference